Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program

Lung Cancer

Volumn 53, Issue 3, 2006, Pages 331-337

  Govindan, Ramaswamy ^a   Natale, Ronald ^b   Wade, James ^c   Herbst, Roy ^d   Krebs, Annetta ^e   Reiling, Richard ^f   Hensing, Thomas ^g   Wozniak, Antoinette ^h   Belani, Chandra P ⁱ   Kelly, Karen ^j   Ochs, Judith ^e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Cancer Care Specialists of Central Illinois   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e ASTRAZENECA   (United Kingdom)

^f Presbyterian Center for Cancer Research   (United States)

^g EVANSTON HOSPITAL   (United States)

^h KARMANOS CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^j UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

Chemonaive; EGFR TKI; Expanded Access Program; Gefitinib; Molecular targeted therapy; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL;

ACNE; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRY SKIN; FEMALE; HEALTH PROGRAM; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUINAZOLINES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33746897725     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.04.013     Document Type: Article

References (23)

1. National Cancer Institute. SEER Cancer Statistics Review 1975-2001: Lung and Bronchus Cancer (Invasive). National Cancer Institute, National Institutes of Health. Available at: http://seer.cancer.gov/csr/1975_2000/results_merged/sect_15_lung_bronchus.pdf. Accessed March 29, 2006.
2. Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?. Lung Cancer 38 Suppl. 2 (2002) S45-S50
3. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectabe non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
4. National Comprehensive Cancer Network. Non-small cell lung cancer. Clinical Practice Guidelines in Oncology, v.1.2004. Jenkintown, PA; 2004.
5. Socinski M.A., Morris D.E., Masters G.A., and Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123 (2003) 226S-243S
6. Spira A., and Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 350 (2004) 379-392
7. Belani C.P., and Langer C. First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer 38 Suppl. 4 (2002) 13-19
8. D'Addario G., Pintilie M., Leighl N.B., Feld R., Cerny T., and Shepherd F.A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23 (2005) 2926-2936
9. Gridelli C., Ardizzoni A., Le Chevalier T., Manegold C., Perrone F., Thatcher N., et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 15 (2004) 419-426
10. Earle C.C., Venditti L.N., Neumann P.J., Gelber R.D., Weinstein M.C., Potosky A.L., et al. Who gets chemotherapy for metastatic lung cancer?. Chest 117 (2000) 1239-1246
11. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the eopidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
12. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21 (2003) 2237-2246
13. ® (ZD1839, gefitinib) Tablets: Oncologic Drugs Advisory Committee (ODAC) Meeting Briefing Document. AstraZeneca. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2_01_01-AstraZeneca-Iressa.pdf. Accessed March 29, 2006.
14. Kris M.G., Herbst R., Rischin D., LoRusso P., Baselga J., Hammond L., et al. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839 (Iressa™), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer 29 Suppl. 1 (2000) 72
15. Hurria A., and Kris M. Management of lung cancer in older adults. CA Cancer J Clin 53 (2003) 325-341
16. DaVinci Healthcare Partners LLC. Treatment Architecture. DaVinci Healthcare Partners LLC. Hayward, CA; 2003.
17. Levin M., Mermelstein H., and Rigberg C. Factors associated with acceptance or rejection of recommendation for chemotherapy in a community cancer center. Cancer Nurs 22 (1999) 246-250
18. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 6 Suppl. 1 (2001) 4-7
19. Anderson H., Hopwood P., Stephens R.J., Thatcher N., Cottier B., Nicholson M., et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 83 (2000) 447-453
20. Roskowski K., Pluzanska A., Krzakowski M., Peter Smith Al, Saigi E., Aasebo U., et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27 (2000) 145-157
21. Sweeney C.J., Zhu J., Sandler A.B., Schiller J., Belani C.P., Langer C., et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic non-small cell lung carcinoma. Cancer 92 (2001) 2639-2647
22. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
23. Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line of 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. (Abstract no.: 7022). Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004. New Orleans, LA.